(Q37931893)

25 August 2017

1 reference

title

Therapeutic potential of PARP inhibitors for metastatic breast cancer (English)

1 reference

25 August 2017

metastatic breast cancer

1 reference

Sheeba Irshad

1

1 reference

PubMed ID

21916578

25 August 2017

Alan Ashworth

series ordinal

2

1 reference

PubMed ID

21916578

25 August 2017

Andrew Tutt

series ordinal

3

1 reference

25 August 2017

1 August 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

1 reference

25 August 2017

11

1 reference

25 August 2017

1243-1251

1 reference

25 August 2017

8

1 reference

25 August 2017

Cancer statistics, 2009

1 reference

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

21 January 2018

1 reference

Genome instability: a mechanistic view of its causes and consequences

21 January 2018

1 reference

Cellular responses to DNA damage

21 January 2018

1 reference

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

21 January 2018

1 reference

Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes

21 January 2018

1 reference

The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction

21 January 2018

1 reference

Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme

21 January 2018

1 reference

In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs)

21 January 2018

1 reference

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase

21 January 2018

1 reference

Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse

21 January 2018

1 reference

Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1

21 January 2018

1 reference

Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

21 January 2018

1 reference

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

21 January 2018

1 reference

Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

21 January 2018

1 reference

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination.

21 January 2018

1 reference

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy

21 January 2018

1 reference

Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia

21 January 2018

1 reference

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks

21 January 2018

1 reference

Integrating genetic approaches into the discovery of anticancer drugs

21 January 2018

1 reference

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

21 January 2018

1 reference

A review of PARP inhibitors: from bench to bedside

21 January 2018

1 reference

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

21 January 2018

1 reference

Targeting DNA repair in breast cancer: a clinical and translational update

21 January 2018

1 reference

Brca1 controls homology-directed DNA repair

21 January 2018

1 reference

BRCA2 is required for homology-directed repair of chromosomal breaks

21 January 2018

1 reference

The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.

21 January 2018

1 reference

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families

21 January 2018

1 reference

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

Histopathology of BRCA1- and BRCA2-associated breast cancer.

21 January 2018

1 reference

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

21 January 2018

1 reference

The influence of basal phenotype on the metastatic pattern of breast cancer.

21 January 2018

1 reference

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

BRCA1 mutations in primary breast and ovarian carcinomas.

21 January 2018

1 reference

BRCA2 mutations in primary breast and ovarian cancers

21 January 2018

1 reference

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

21 January 2018

1 reference

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

21 January 2018

1 reference

Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers

21 January 2018

1 reference

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

21 January 2018

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer

21 January 2018

1 reference

Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes

21 January 2018

1 reference

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer

21 January 2018

1 reference

Metastatic soft tissue sarcoma diagnosed by small bowel video capsule endoscopy

21 January 2018

1 reference

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

21 January 2018

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

Targeting homologous recombination repair defects in cancer

21 January 2018

1 reference

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways

21 January 2018

1 reference

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.52

1 reference

25 August 2017

1 reference

PubMed ID

21916578